Retatrutide vs Tirzepatide
Research Compound Comparison

Retatrutide and Tirzepatide at a Glance

Both compounds are supplied by North Peptides UK as lyophilised (freeze-dried) powder in sealed vials, listed with supplier-stated 99%+ purity and stored frozen until dispatch. The table below summarises how they compare as research materials before we look at each attribute in detail.

The Core Difference: Receptor Targets

The defining difference between the two compounds is the set of receptors they act on. This is what researchers are usually comparing when they weigh one against the other.

Tirzepatide is a dual agonist. As a single molecule it engages both the GIP (glucose-dependent insulinotropic polypeptide) receptor and the GLP-1 (glucagon-like peptide-1) receptor. It is widely used as a reference compound in metabolic receptor-signalling research because it combines two incretin pathways in one sequence.

Retatrutide extends this profile to three receptors. In addition to GLP-1 and GIP, it also acts on the glucagon receptor, which is why it is described as a triple agonist or "tri-agonist". For a research model designed to probe glucagon-receptor involvement alongside the two incretin pathways, Retatrutide is the compound that covers all three targets in a single molecule.

In short: if a study is concerned only with the GIP and GLP-1 pathways, Tirzepatide is the more targeted choice. If the glucagon receptor is also part of the experimental question, Retatrutide adds that third pathway.

How Each Is Supplied

Both are supplied as lyophilised powder, the most stable format for transport and storage. North Peptides UK stocks the following vial sizes:

• Retatrutide — 10mg, 15mg and 20mg vials, from £45. Supplier-stated 99%+ purity with supplier documentation available on request where held.
• Tirzepatide — 15mg and 30mg vials, from £65. Supplier-stated 99%+ purity with supplier documentation available on request where held.

Each batch is stored frozen until dispatch and shipped from the UK with tracked delivery, typically within 24 hours on business days. The larger vial sizes are usually selected where a research protocol calls for a higher total quantity of material per vial.

Handling and Reconstitution

Both compounds are handled in the same way in the laboratory. As lyophilised powders they are reconstituted with bacteriostatic water before use in a research preparation. Both dissolve readily; a 2ml to 4ml volume of solvent per vial is a common working dilution when preparing material for laboratory use.

The handling principles are identical to any peptide of this class: direct the solvent down the inside wall of the vial rather than onto the powder, swirl gently rather than shake, and label the vial with the preparation date. Our reconstitution guide covers the full procedure and the concentration arithmetic for each vial size.

Stability and Storage

In lyophilised form, both compounds are stable and are kept frozen for longer-term storage. The difference in handling appears only after reconstitution:

• Before reconstitution — keep the sealed vial frozen and away from light. The freeze-dried powder is the most stable state and tolerates transport at room temperature for short periods.
• After reconstitution — refrigerate the prepared solution at 2–8°C, keep it out of direct light, and avoid repeated freeze–thaw cycles, which place mechanical stress on the molecule.

Neither compound is more fragile than the other in this respect; they follow the same stability rules as the wider peptide class.

Choosing Between Them for a Research Model

The decision usually comes down to the experimental question rather than any difference in handling or quality, since both are supplied at the same stated purity. A few considerations researchers commonly weigh:

• Pathway coverage — Tirzepatide isolates the GIP and GLP-1 pathways; Retatrutide adds glucagon-receptor activity. The model's design dictates which is appropriate.
• Reference comparability — Tirzepatide has a longer track record as a dual-agonist reference compound, which can matter when a study is being compared against existing literature.
• Quantity per vial — available vial sizes differ (10–20mg for Retatrutide, 15–30mg for Tirzepatide), which affects how many preparations a single vial yields.
• Availability — both are UK stocked with 24-hour dispatch, so lead time is not usually a differentiator.

Some research programmes hold both on hand precisely so the same protocol can be run across the dual- and triple-agonist profiles for comparison.

Sourcing Both in the UK

North Peptides UK stocks both compounds domestically, so there are no import delays or customs handling for UK-based researchers. Every batch is listed with supplier-stated 99%+ purity, stored frozen until dispatch, and documented with supplier paperwork available on request where held.

Orders are dispatched within 24–48 hours of confirmed payment on business days with tracked delivery. If you need help confirming vial sizes or purity documentation before ordering, you can reach the team directly on Telegram at @NORTHPEPTIDESUK.

Frequently Asked Questions